The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Female and male patients who receive Ultravist® for coronary angiography or PCI can be included in the study

Exclusion Criteria:

• Patients who are or are suspected in pregnancy or nursery

• Patients with the contraindications for Ultravist

• Patients with the contraindications for cardiac catheterization